Drug intelligence / Profile preview

mRNA-1851

Development stage: Phase 1
Lead developer: Valera
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**mRNA-1851** is an investigational mRNA vaccine developed by Moderna for prophylaxis against influenza A H7N9 subtype infections, a strain with pandemic potential. It encodes the hemagglutinin glycoprotein of the H7N9 influenza virus to elicit immune responses, functioning as both a hemagglutinin inhibitor and immunostimulant. The vaccine demonstrated tolerability and strong humoral immunogenicity in early clinical data, advancing as one of Moderna's first mRNA vaccine candidates targeting influenza.[1][4][5][7]

Other names: H7 mRNA vaccineH-7 mRNA vaccineH 7 mRNA vaccineVAL 339851VAL339851VAL-339851

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on mRNA-1851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1851.

Explore the full profile